Literature DB >> 18448772

Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis.

Erin E Krebs1, Bradley N Gaynes, Gerald Gartlehner, Richard A Hansen, Patricia Thieda, Laura C Morgan, Angela DeVeaugh-Geiss, Kathleen N Lohr.   

Abstract

BACKGROUND: Approximately two-thirds of patients with depression experience physical pain symptoms. Coexisting pain complicates the treatment of depression and is associated with worse depression outcomes.
OBJECTIVE: The authors reviewed the effect of newer antidepressants on pain in patients with depression.
METHOD: The authors searched systematically for trials of second-generation antidepressants that enrolled depression patients and reported pain outcomes, pooling changes on the pain visual-analog scale (VAS), using random-effects models.
RESULTS: Eight trials were eligible. Pooled analysis of head-to-head trials showed no difference in VAS between duloxetine and paroxetine. Both drugs were superior to placebo.
CONCLUSION: The authors found insufficient evidence to support the choice of one second-generation antidepressant over another in patients with pain accompanying depression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448772     DOI: 10.1176/appi.psy.49.3.191

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  12 in total

1.  Interrelationship between measures of pain reactions in inflammation and levels of depression in prenatally stressed rat pups.

Authors:  V A Mikhailenko; I P Butkevich; E A Vershinina; P O Semenov
Journal:  Neurosci Behav Physiol       Date:  2009-12-22

2.  Trait body shame predicts health outcomes in college women: A longitudinal investigation.

Authors:  Jean M Lamont
Journal:  J Behav Med       Date:  2015-07-23

Review 3.  Psychiatry and Pain Management: at the Intersection of Chronic Pain and Mental Health.

Authors:  Jenna Goesling; Lewei A Lin; Daniel J Clauw
Journal:  Curr Psychiatry Rep       Date:  2018-03-05       Impact factor: 5.285

4.  Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials.

Authors:  Susan G Ball; Durisala Desaiah; Melissa E Spann; Qi Zhang; James M Russell; Michael J Robinson; Koen Demyttenaere
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 5.  Pain and depression: an integrative review of neurobiological and psychological factors.

Authors:  Jenna Goesling; Daniel J Clauw; Afton L Hassett
Journal:  Curr Psychiatry Rep       Date:  2013-12       Impact factor: 5.285

6.  Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.

Authors:  Daniel Z Lieberman; Suena H Massey
Journal:  Core Evid       Date:  2010-06-15

7.  Pharmacologic management of chronic pain.

Authors:  Hue Jung Park; Dong Eon Moon
Journal:  Korean J Pain       Date:  2010-05-31

8.  Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial.

Authors:  Kurt Kroenke; Matthew J Bair; Teresa M Damush; Jingwei Wu; Shawn Hoke; Jason Sutherland; Wanzhu Tu
Journal:  JAMA       Date:  2009-05-27       Impact factor: 56.272

Review 9.  The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis.

Authors:  Gerald Gartlehner; Kylie Thaler; Richard A Hansen; Bradley N Gaynes
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Observational evidence that urbanisation and neighbourhood deprivation are associated with escalation in chronic pharmacological pain treatment: a longitudinal population-based study in the Netherlands.

Authors:  Carsten Leue; Servaas Buijs; Jacqueline Strik; Richel Lousberg; Jasper Smit; Maarten van Kleef; Jim van Os
Journal:  BMJ Open       Date:  2012-07-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.